AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior listings and versions of claims in this application.

1. (Original) A clonal lentogenic oncolytic strain of Newcastle Disease Virus (NDV) comprising the DNA nucleotide sequence of SEQ ID NO: 1 encoding for the fusion (F) gene and at least part of the hemaglutinin-neuraminidase (HN) gene.

2. (Previously presented) A pharmaceutical composition for the treatment of cancer comprising as an active ingredient a lentogenic oncolytic strain of Newcastle Disease Virus (NDV).

3. (Previously presented) The pharmaceutical composition according to claim 2 further comprising a suitable carrier.

4. (Previously presented) The composition according to claim 2 wherein the lentogenic strain of NDV is the HUJ strain.

5. (Original) The composition according to claim 4 comprising $10^6 - 10^{12}$ EID_{50} per unit dose.

6. (Original) The composition according to claim 2 further comprising at least one isolated viral glycoprotein having oncolytic activity.

7. (Original) The composition according to claim 6 wherein the at least one viral glycoprotein is from NDV.

8. (Original) The composition according to claim 7 wherein the at least one viral glycoprotein is the F glycoprotein of NDV.

9. (Original) The composition according to claim 7 wherein the at least one viral glycoprotein is the HN glycoprotein of NDV.

10. (Currently amended) The composition according to claim ~~[claims]~~ 7 further comprising the F glycoprotein and hemaglutinin-neuraminidase (HN) glycoprotein of NDV.

11. (Currently amended) The composition according to claim ~~[claims]~~ 7 wherein the viral glycoprotein is from a velogenic strain of NDV.

12. (Currently amended) The composition according to claim ~~[claims]~~ 7 wherein the viral glycoprotein is from a mesogenic strain of NDV.

13. (Currently amended) The composition according to claim ~~[claims]~~ 7 wherein the viral glycoprotein is from a lentogenic strain of NDV.

14. (Original) The composition according to claim 13 wherein the lentogenic strain of NDV is the HUJ strain.

15. (Original) A composition for the treatment of cancer comprising at least one isolated viral glycoprotein or a subunit or analog thereof having oncolytic activity and a suitable carrier.

16. (Previously presented) The composition according to claim 15 wherein the at least one viral glycoprotein is from Newcastle Disease Virus (NDV).

17. (Currently amended) The composition according to claim 16 wherein the at least one viral glycoprotein is the fusion [[gene]] glycoprotein of Newcastle Disease Virus (NDV).

18. (Previously presented) The composition according to claim 16 wherein the at least one viral glycoprotein is the hemaglutinin-neuraminidase glycoprotein of NDV.

19. (Previously presented) The composition according to claim 15 further comprising the F glycoprotein and hemaglutinin-neuraminidase glycoprotein of Newcastle Disease Virus (NDV).

20. (Original) The composition according to claim 16 wherein the viral glycoprotein is from a velogenic strain of NDV.

21. (Original) The composition according to claim 16 wherein the viral glycoprotein is from a mesogenic strain of NDV.

22. (Original) The composition according to claim 16 wherein the viral glycoprotein is from a lentogenic strain of NDV.

23. (Previously presented) The composition according to claim 22 wherein the lentogenic strain of NDV is the HUJ strain.

24. (Original) A method for treating cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 2.

25. (Original) The method of claim 24 wherein the step of administering is selected from intravenous, oral, buccal, intranasal, inhalation, topical application to a mucosal membrane or injection, including intradermal, intrathecal, intracisternal, and intralesional injection.

26. (Previously presented) The method of claim 24 wherein the step of administering comprises locally administering the composition to a tumor or in its vicinity.

27. (Previously presented) The method of claim 24 wherein the composition comprises a lentogenic oncolytic strain of NDV.

28. (Previously presented) The method of claim 27 wherein the lentogenic oncolytic strain of NDV is the HUJ strain.

29. (Previously presented) The method of claim 28 wherein the composition comprises $10^6 - 10^{12}$ EID_{50} per unit dose.

30. (Previously presented) The method of claim 28 wherein the step of administering comprises administering the HUJ strain of NDV in a range of 20 EID_{50}/cell to 2000 EID_{50}/cell.

31. (Currently amended) A method for treating cancer in a patient which comprises administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising as [[an]] active ~~ingredient~~ ingredients a lentogenic oncolytic strain of Newcastle Disease Virus (NDV) and at least one isolated viral glycoprotein having oncolytic activity.

32. (Previously presented) The method of claim 31, wherein the lentogenic oncolytic strain of NDV is the HUJ strain.

33. (Previously presented) The method of claim 31, wherein the at least one viral glycoprotein is from NDV.

34. (Currently amended) The method of claim 33, wherein the at least one viral glycoprotein is the fusion [[gene]] glycoprotein of NDV.

35. (Previously presented) The method of claim 33, wherein the at least one viral glycoprotein is the hemaglutinin-neuraminidase glycoprotein of NDV.

36. (Currently amended) The method of claim 33 further comprising the fusion [[gene]] glycoprotein and hemaglutinin-neuraminidase ~~[[HN]~~ glycoprotein of NDV.

37. (Cancelled)

38. (Previously presented) The method of claim 33, wherein the viral glycoprotein is from a velogenic strain of NDV.

39. (Previously presented) The method of claim 33, wherein the viral glycoprotein is from a mesogenic strain of NDV.

40. (Previously presented) The method of claim 33, wherein the viral glycoprotein is from a lentogenic strain of NDV.

41. (Previously presented) The method of claim 39, wherein the lentogenic strain of NDV is the HUJ strain.

42. (Previously presented) The method of claim 31, wherein the step of administering is selected from intravenous, oral, buccal, intranasal, inhalation, topical application to a mucosal membrane or injection including intradermal, intrathecal, intracisternal, and intralesional injection.

43. (Previously presented) The method of claim 31, wherein the step of administering comprises locally administering the composition to a tumor or in its vicinity.

44. (Previously presented) The method of claim 32, wherein the composition comprises $10^6 - 10^{12}$ EID_{50} per unit dose.

45. (Previously presented) The method of claim 32, wherein the step of administering comprises administering the HUJ strain of NDV in a range of 20 EID_{50}/cell to 2000 EID_{50}/cell.

46. (Previously presented) A method for treating cancer in a patient comprising administering to the patient in need thereof at least one isolated polynucleotide encoding at least one viral polypeptide, an analog or subunit thereof having oncolytic activity.

47. (Currently amended) The method of claim 45, wherein the at least one isolated polynucleotide encodes the fusion [[gene]] glycoprotein of Newcastle Disease Virus.

48. (Previously presented) The method of claim 45, wherein the at least one isolated polynucleotide encodes the hemaglutinin-neuraminidase glycoprotein of Newcastle Disease Virus.

49. (Currently amended) The method of claim 45, wherein a combination of polynucleotides is administered to the patient, wherein the combination includes an isolated polynucleotide encoding the fusion [[gene]] glycoprotein of Newcastle Disease Virus (NDV) and an isolated polynucleotide encoding the hemaglutinin-neuraminidase glycoprotein of NDV.

50. (Previously presented) The method of claim 45, which comprises administering to the patient at least one vector that comprises the at least one isolated polynucleotide encoding at least one viral polypeptide, or an analog or subunit thereof having oncolytic activity.

51. (Previously presented) The method of claim 49, wherein the vector is a viral vector.

52. (Previously presented) The method of claim 49, wherein the vector is an expression vector.

53. (Previously presented) A method for treating cancer in a patient comprising administering to the patient in need thereof a host cell transfected with an isolated polynucleotide, the isolated polynucleotide encodes at least one viral polypeptide, an analog, or subunit thereof having oncolytic activity, the at least one viral polypeptide or an analog or subunit thereof being expressed in the host cell.

54. (Previously presented) A method for treating cancer in a patient comprising administering to the patient in need thereof a host cell transfected with a vector, the vector comprising an isolated polynucleotide encoding at least one viral polypeptide or an analog or subunit thereof having oncolytic activity, wherein the at least one viral polypeptide or an analog or subunit thereof being expressed in the host cell.

55. (Previously presented) A method of making a cancer treatment composition which comprises incorporating in the composition an isolated viral glycoprotein or a subunit or analog thereof having oncolytic activity or of an isolated polynucleotide encoding the same.